title: Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?
authors.affiliation: University of Maryland Greenebaum Cancer Center, Baltimore, 22 S. Greene Street, S9D04B, Baltimore, MD 21201, USA +1 410 328 2567 +1 410 328 6896 vduong@umm.edu.
authors.forename: Vu H
authors.initials: VH
authors.lastname: Duong
authors.forename: Eric
authors.initials: E
authors.lastname: Padron
authors.forename: Alan F
authors.initials: AF
authors.lastname: List
authors.forename: Rami S
authors.initials: RS
authors.lastname: Komrokji
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000201:enzymology*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases